Relmada Therapeutics, Inc.

RLMD · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$80-$99-$157-$126
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$30$0$44$40
Change in WC-$2$3$11-$8
Other Non-Cash-$0$44-$2$1
Operating Cash Flow-$52-$52-$104-$92
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$12-$90-$47-$223
Inv. Sales/Matur.$64$141$67$169
Other Inv. Act.$0$0$0$0
Investing Cash Flow$52$50$20-$54
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$43$185
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$0-$0$2$3
Financing Cash Flow-$0-$0$45$188
Forex Effect$0-$0$0$0
Net Chg. in Cash-$0-$1-$39$42
Supplemental Information
Beg. Cash$4$5$44$2
End Cash$4$4$5$44
Free Cash Flow-$52-$52-$104-$92